March 7, 2022 - "US-PCT: Best Practices and Common Mistakes at the USPTO" (IPWatchdog) - 11:00 am (EST)
March 8, 2022 - "The International IP Landscape 2022" (IPWatchdog) - 8:45 am (EST)
Contributors
Juristat #4 Overall Rank
Contact the Docs
Foreign Correspondents
Recent Posts
- Eye Therapies LLC v. Slayback Pharma, LLC (Fed. Cir. 2025)
- Government Files Statement in Support of Preliminary Injunction Motion in Radian Memory Systems v. Samsung Electronics
- MSN Laboratories Private Ltd. v. Bausch Health Ireland Ltd. (Fed. Cir. 2025)
- Edwards Lifesciences Corp. v. Cardiovalve Ltd. (Fed. Cir. 2025)
- Agilent Technologies, Inc. v. Synthego Corp. (Fed. Cir. 2025)
- Subject Matter Eligibility in the 21st Century: Echoes of pre-§ 103 Obviousness*
- Dancing with Abstract Ideas: Patent Eligibility in 2025
- Treprostinil Saga Continues
- Microprocessor v. Abacus: The Fictional Patent-Eligibility Debate between a Patent Attorney and a Retired Supreme Court Justice
- Federal Trade Commission Continues Efforts to Delist Drug Device Administration Patents in Orange Book
Disclaimer
- "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank
- Powered By Invesp
« Webinar on Best Practices When Entering U.S. National Stage Through the PCT | Main | Ukrpatent Continues Normal Operations Despite Russian Aggression »
March 06, 2022
The comments to this entry are closed.
July 2025
Categories
- Artificial Intelligence (20)
- Best Mode (2)
- Biosimilars (247)
- Biotech/Pharma Business (175)
- Biotech/Pharma News (278)
- Board of Patent Appeals and Interferences (12)
- Claim Construction (109)
- Conferences & CLE's (2977)
- Copyright (4)
- Court Report (507)
- Damages (37)
- Definiteness (27)
- District Court (225)
- Double Patenting (42)
- Enablement (54)
- Federal Circuit (1046)
- Food and Drug Administration (113)
- Hatch-Waxman (96)
- Inequitable Conduct (52)
- Infringement - Contributory or Induced (29)
- Infringement - Literal or DOE (93)
- Injunction (40)
- International IP (297)
- Inventorship (17)
- Licensing (129)
- Media Commentary (71)
- Miscellaneous (169)
- News from Abroad (102)
- Novelty (77)
- Obviousness (242)
- Patent Exhaustion (3)
- Patent Legislation (312)
- Patent Litigation (219)
- Patent Office Rules & Procedures (833)
- Patent Profiles (104)
- Patent Prosecution (100)
- Patent Prosecution - International (26)
- Patent Research (4)
- Patent Trial and Appeal Board (373)
- Patentable Subject Matter (650)
- Personalized Medicine (5)
- Post-Grant Proceedings (159)
- PTAB Report (9)
- Study/Report (8)
- Supreme Court (265)
- Tools (5)
- Trade Secrets (13)
- Utility (4)
- Venue (11)
- Written Description (90)
Patent Resources
Patent Search
- Patent Search
Patent Blogs & Sites
- 717 Madison Place
- America-Israel Patent Law
- Anticipate This!
- BlawgIT
- Chicago IP Litigation Blog
- FedCircuitBlog
- Global Patent Quality
- Innovation Alliance
- Intellectual Property Watch
- IP Dragon
- IPcopy
- McCabe Ali LLP
- IPWatchdog.com
- Life Science IP
- Orange Book Blog
- Patent Blurb
- Patently-O
- Patentology
- Patents4Life
- Reexamination Center
- Intellepedia – IP News Center
- SPICY IP
Comments